PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients

Post-market, prospective, observational, multicenter, non-intervention study, to demonstrate the effectiveness of drug-coated ballon (DCB)therapy in real-world patients with small native vessel coronary artery disease, and to demonstrate the safety of short dual antiplatelet therapy (7 days) in high-bleeding risk patients with native small vessel coronary artery disease treated with DCB therapy. A percutaneous coronary intervention (PCI) with DCB will be performed in patients with native vessel coronary artery disease based on the criterion of the treating physician.

Post-market, prospective, multicenter, non-intervention study, to demonstrate the effectiveness of drug-coated ballon therapy in real-world patients with small native vessel coronary artery disease, and to demonstrate the safety of short dual antiplatelet therapy (7 days) in high-bleeding risk patients with native small vessel coronary artery disease treated with DCB therapy. A PCI with DCB will be performed in patients with native vessel coronary artery disease based on the criterion of the treating physician. The angiographic study will be analyzed in a core lab (icicorelab) blinded to the procedural outcomes and the patients' follow-up. As per clinical practice, 1-year clinical follow-up of all the patients will be conducted with a first assessment at 30 days, a second assessment at 6 months, and one final assessment at 12 months. Should the patient have an elevated bleeding risk -defined as concomitant therapy with oral anticoagulation or a PRECISE-DAPT score ≥ 25- patients will be included in a high-bleeding risk substudy. The antiplatelet therapy regime will be administered according to the local investigator and the treating medical team.

Inclusion Criteria: Patients with: * PCI with DCB on native arteries with diameters \< 3 mm. * Indication for PCI in acute coronary syndrome or chronic coronary syndrome or silent angina with an indication for PCI. syndrome or silent angina with an indication for PCI. * If previous lesion preparation was required after which angiographic residual lesion should not exist with diameter stenosis \> 30% or flow-limiting coronary dissections. * All antithrombotic therapies administered prior to the procedure are accepted. Still, they can be changed after the procedure. * Capacity to understand and sign the written informed consent. * If the patient has a high-bleeding risk defined by 1) PRECISE-DAPT SCORE ≥ 25 or 2) an indication for concomitant oral anticoagulation he can be included in the high- bleeding risk substudy as long as he does not meet the specific exclusion criteria. Exclusion Criteria: Patients with: * Concomitant lesions on vessels \> 3 mm in diameter in the same coronary territory. * PCI on in-stent restenoses. * PCI on culprit lesions of acute coronary syndrome with ST segment elevation. * Patients with an indication for PCI on additional non-culprit lesions of acute coronary syndrome with ST segment elevation may be included in the study, if only non-culprit lesions are considered for the study. * Life expectancy \<12 months * Pregnancy. * Participation in clinicaltrials. * Inability to give the written informed consent. * Specific exclusion criteria for the high-bleeding risk patient subgroup: * Past medical history of stent thrombosis. * Indication for dual antiplatelet therapy for a different reason.